IP Library › Granted Patent US 12,296,170
Granted Patent B2
US 12,296,170 · App. 18/162,999 · Granted May 13, 2025

Systems and methods for neuromodulation of a carotid sinus nerve

Inventors: Silvia Margarida Vilares Santos Conde (Lisbon, PT); Daniel John Chew (Stevenage, GB); Hans Jakob Kristoffer Famm (Stevenage, GB); Maria Pedro Sucena Guarino (Lisbon, PT); Brad Holinski (San Jose, CA); Sonal Patel (Stevenage, GB)
Assignees: Presidio Medical, Inc.; Faculdade De Ciências Médicas Da Universidade Nova De Lisboa
A61N1/36085A61N1/36A61N1/36034A61N1/3605A61N1/3606A61N1/36171A61N1/05A61N1/36157
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,296,170
App. No.
18/162,999
Granted
May 13, 2025
Kind
B2
Abstract

The invention refers to a device for inhibiting the neural activity of a carotid sinus nerve (CSN) or carotid body of a subject, the device comprising: one or more transducers configured to apply a signal to the CSN or associated carotid body of the subject, optionally at least two such transducers; and a controller coupled to the one or more transducers, the controller controlling the signal to be applied by the one or more transducers, such that the signal inhibits the neural activity of the CSN or carotid body to produce a physiological response in the subject, wherein the physiological response is one or more of the group consisting of: an increase in insulin sensitivity in the subject, an increase in glucose tolerance in the subject, a decrease in (fasting) plasma glucose concentration in the subject, a reduction in subcutaneous fat content in the subject, and a reduction in obesity in the subject.

Claims (24)

1. A device for inhibiting the neural activity of a carotid sinus nerve (CSN) or carotid body of a subject, the device comprising:

one or more electrodes configured to apply an electrical signal to the CSN or associated carotid body of the subject; and

a controller coupled to the one or more electrodes, the controller controlling the electrical signal to be applied by the one or more electrodes, such that the electrical signal inhibits the neural activity of the CSN or carotid body to produce a physiological response in the subject,

wherein the electrical signal comprises a gradually ramped-up and charge-balanced direct current (DC) waveform such that the one or more electrodes are configured to deliver net neutral charge.

2. A device according to claim 1 , wherein the physiological response is one or more from the group consisting of: an increase in insulin sensitivity in the subject, an increase in glucose tolerance in the subject, a decrease in plasma glucose concentration in the subject, a reduction in subcutaneous fat content in the subject, and a reduction in obesity in the subject,

wherein a level of current of the DC waveform varies, at a frequency of 5 Hz to 15 Hz, between delivering positive and negative charge.

3. A device according to claim 2 , wherein the level of DC current varies, at a frequency of 10 Hz, between delivering positive and negative charge.

4. A device according to claim 1 , wherein the electrode is a cuff electrode or a bipolar cuff electrode.

5. A device according to claim 1 , wherein the device is suitable for at least partial implantation into the subject.

6. A device according to claim 1 , wherein the device is suitable to be wholly implanted into the subject.

7. A method of inhibiting neural signaling in the CSN of a subject comprising:

i. implanting in the subject a device for inhibiting the neural activity of a carotid sinus nerve (CSN) or carotid body of a subject, the device comprising:

one or more transducers configured to apply a signal to the CSN or associated carotid body of the subject; and

a controller coupled to the one or more transducers, the controller controlling the signal to be applied by the one or more transducers, such that the signal inhibits the neural activity of the CSN or carotid body to produce a physiological response in the subject,

wherein the signal comprises a gradually ramped-up and charge-balanced direct current (DC) waveform such that the one or more transducers are configured to deliver net neutral charge;

ii. positioning at least one transducer of the device in signaling contact with a CSN or carotid body of the subject; and

iii. activating the device.

8. A method according to claim 7 , wherein positioning at least one transducer of the device comprises positioning a first transducer in signaling contact with the left carotid sinus nerve (CSN) and/or left carotid body of said subject to modulate the neural activity of the left CSN in the subject, and positioning a second transducer in signaling contact with the right carotid sinus nerve (CSN) and/or right carotid body of said subject to modulate the neural activity of the right CSN in the subject.

9. A method according to claim 7 , wherein the physiological response is one or more from the group consisting of: an increase in insulin sensitivity in the subject, an increase in glucose tolerance in the subject, a decrease in plasma glucose concentration in the subject, a reduction in subcutaneous fat content in the subject, and a reduction in obesity in the subject,

wherein a level of current of the DC waveform varies, at a frequency of 5 Hz to 15 Hz, between delivering positive and negative charge.

10. A method of treating a condition associated with impaired glucose control in a subject, the method comprising applying a signal to a part or all of a carotid sinus nerve (CSN) and/or a carotid body of said subject to inhibit the neural activity of a CSN in the subject,

wherein the signal is an electrical current and, when the signal is applied by a neuromodulation device comprising one or more transducers for applying the signal, each transducer configured to apply the signal is an electrode, wherein the signal comprises a gradually ramped-up and charge-balanced direct current (DC) waveform.

11. A method according to claim 10 , wherein a level of current of the DC waveform varies, at a frequency of 5 Hz to 15 Hz, between delivering positive and negative charge.

12. A method according to claim 10 , wherein a level of current of the DC waveform varies, at a frequency of 10 Hz, between delivering positive and negative charge.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 24, 2023
From: GALVANI BIOELECTRONICS LIMITED
To: PRESIDIO MEDICAL, INC.
Reel/Frame 062801/0707 →
Continuity (3)
Continuation 15523914
Provisional Application 62074136 · Nov 3, 2014
Related Publication 20240066299A1 · Feb 29, 2024
References Cited (17)
US 5231988A · Wernicke · 1993 [cited by examiner]
US 5540734A · Zabara · 1996 [cited by examiner]
US 7389145B2 · Kilgore et al. · 2008 [cited by applicant]
US 8731676B2 · Fang et al. · 2014 [cited by applicant]
US 11577080B2 · Conde · 2023 [cited by examiner]
US 20140214129A1 · Waataja et al. · 2014 [cited by applicant]
Bhadra et al., “Direct current electrical conduction block of peripheral nerve”, IEEE Transactions on Neural systems and rehabilitation engineering, vol. 12, No. 3, dated Sep. 2004, pp. 313-324. [cited by applicant]
Bhadra et al., “Simulation of high-frequency sinusoidal electrical block of mammalian myelinated axons”, Journal of Computational Neuroscience, vol. 22, No. 3, dated Jun. 2007, pp. 313-326. [cited by applicant]
Duke et al., “Spatial and temporal variability in response to hybrid electro-optical stimulation”, Journal of Neural Engineering< vol. 9, No. 3, dated Jun. 2012, pp. 036003. [cited by applicant]
Fern et al., “The effects of compression upon conduction in myelinated axons of the isolated frog sciatic nerve” , Anaesth. vol. 47, dated 1975, pp. 1123. [cited by applicant]
Kilgore et al., “Nerve conduction block utilising high-frequency alternating current”, Medical and Biological Engineering and Computing, vol. 42, No. 3, dated May 2004, pp. 394-406. [cited by applicant]
Kramer et al., “Optogenetic pharmacology for control of native neuronal signaling proteins”, Nature Neuroscience, vol. 16, No. 7, dated Jul. 2013, pp. 816-823. [cited by applicant]
Limberg et al., “Is insulin the new intermittent hypoxia?”, Med Hypotheses, vol. 82, No. 6, dated Jun. 2014, pp. 730-735. [cited by applicant]
McBryde, F.D., et al., “The carotid body as a putative therapeutic targe for the treatment of neurogenic hypertension,” Nature Communications, vol. 4, Article No. 2395, Sep. 3, 2013, in 36 pages. [cited by applicant]
Patberg et al., “Blocking of impulse conduction in peripheral nerves by local cooling as a routine in animal experimentation”. Journal of Neuroscience Methods, vol. 10, No. 4, dated Apr. 1984, pp. 267-275. [cited by applicant]
Ribeiro et al., “Carotid Body Denervation Prevents the Development of Insulin Resistance and Hypertension Induced by Hypercaloric Diets”, Diabetes, vol. 62, No. 8, dated Aug. 2013, pp. 2905-2916. [cited by applicant]
Ritter et al., “WONOEP appraisal: optogenetic tools to suppress seizures and explore the mechanisms of epileptogenesis”, Epilepsia, vol. 55, No. 11, dated Nov. 2014, pp. 1693-1702. [cited by applicant]